Parametrization by nonlinear regression analysis of the active acid metabolite of ebastine using different weighting methods

International Journal of Clinical Pharmacology and Therapeutics

Volumn 34, Issue 12, 1996, Pages 546-549

  Marino E L ^a   Jansat, J M ^b   March, M A ^a   Lastra, C F ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Laboratorios Almirall ^*  (Spain)

Author keywords

Ebastine; Nonlinear regression; Parametric estimation

Indexed keywords

EBASTINE;

ADULT; ANALYTICAL ERROR; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; REGRESSION ANALYSIS; SOLID PHASE EXTRACTION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; BUTYROPHENONES; HALF-LIFE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; METABOLIC CLEARANCE RATE; PIPERIDINES; REGRESSION ANALYSIS;

EID: 0030477162     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ankier SI, Warrington SJ 1989 A double-blind placebo contolled study of the efficacy and tolerability of ebastina against hay fever in general practice patients. J Intern Med 226: 453-458
2. Atkins GL 1974 Weighting functions and data truncation in the fitting of multi-exponential functions. Biochem J 138: 125-127
3. Berga P, Puig J, Fernandez AG, Massingham R 1992 Preclinical safety studies with ebastina. I. Pharmacological effects on the central nervous system. Drugs of Today 28 (Suppl B): 23-27
4. Colino CL, Lastra CF, López FG, Ledesma A, Mariño EL 1991 Open-loop feedback control of serum entazepam concentrations and Bayesian estimation in multiple dosage regimens in patients. Int J Clin Pharmacol Ther Toxicol 29: 457-462
5. 1 antihistamines. Clin Pharmacokinet 28: 419-432
6. Draper NR, Smith H 1981 Applied regression analysis (2nd ed). Wiley, New York
7. Fernández C, López FG, Dominguez-Gil A, Mariño EL 1988 Discrimination of kinetic models in heteroscedastic parametric estimation of bentazepam following multiple dosing. Int J Clin Pharmacol Ther Toxicol 26: 335-338
8. Gomeni R, Gomeni C 1978 IGPHARM: interactive graphic package for pharmacokinetic analysis. Comp Biomed Res 11: 345-61
9. Jelliffe RW 1989 Explicit determination of laboratory assay error patterns - A useful aid in therapeutic drug monitoring. Drug Monitor Toxicol 10: 1-5
10. Llupia J, Bou J, Fernandez AG, Llenas J, Puig J, Berga P, Massingham R, Roberts DJ 1992 Antihistamine, antiallergic and related pharmacological properties of ebastina, a new selective antihistamine H1-receptor agonist. Drugs of Today 8 (Suppl B): 11-21
11. Luria X, Bakke O 1992 Ebastine: overview of clinical trials. Drugs of Today 28 (Suppl B): 69-78
12. Mariño EL, Fernández C, Gonzalez F, Dominguez-Gil A, Garcia JL, Lorca G, Izquierdo JA, Ledesma-Jimeno A 1987 Parametrization by nonlinear regression and bayesian estimation of bentazepam in multiple dosage regimen in humans. Int J Clin Pharmacol Ther Toxicol 25: 627-632
13. Martinez-Tobed A, Tarrus E, Segura J, Roberts DJ 1992 Pharmacokinetic studies of ebastina in rats, frogs and man. Drugs of Today 28 (Suppl B): 56-67
14. Moragues J, Roberts D 1990 Ebastine. Drugs Fut 15: 674-679
15. Peck C, Beal SL, Sheiner BL, Nichols AJ 1984 Extended least squares nonlinear regresion: A possible solution to the "choice of weights" problem in analysis of individual pharmacokinetic data. J Pharmacokin Biopharm 12: 545-548
16. Peck CC 1984 The problem of choosing weights in nonlinear regression analysis of pharmacokinetic data. Drug Metabol Rev 15: 133-148
17. Powell MJD 1964 A method for minimizing a sum of squares of nonlinear functions without calculating derivates: Comput J 7: 303-307
18. Powers JD 1993 Statistical considerations in pharmacokinetic study design. Clin Pharmacokinet 24: 380-387
19. Pritchard DJ, Downie J, Bacon DW 1977 Further considerations of heteroscedasticity in fitting kinetic models. Technometrics 19: 227-236
20. Roberts DJ, Spickett RWJ, Moragues J, Celdran E 1987 Ebastine, a new nonsedative antihistamine. Xth International Congress of Pharmacology, Sydney, Australia, Abstr P1006
21. Sheiner L, Beal SL 1985 Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J Pharmacokin Biopharm 13: 185-201
22. 1 antagonist ebastine in children. J Allergy Clin Immunol 91: 258
23. Thomson AH, Kelman AW, Whiting B 1985 Evaluation of nonlinear regression with extended least squares: simulation study. J Pharm Sci 74: 1327-1330
24. Van Houwelingen JC 1988 Use and abuse of variance models in regression. Biometrics 44: 1073-1081
25. Vincent J, Limiñana R, Meredith PA, Reid JL 1988 The pharmacokinetics, antihistamine and concentration-effect relationship of ebastina in healthy subjects. Br J Clin Pharmacol 26: 497-501
26. Vincent J, Sumner DJ, Reid JL 1988 Ebastine: the effect of a new antihistamine on psychomotor performance and automatic responses in healthy subjects. Br J Clin Pharmacol 26: 503-508
27. Wood-Bake R, Holgate ST 1990 Dose response relationship of the H-1-histamine antagonist ebastina against histamine and methacholine-induced bronchoconstriction in patients with asthma. Agents Actions 30: 284-286
28. Yamaoka K, Nakagawa T, Uno T 1978 Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharm Biopharm 6: 165-172
29. 1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects. Arzneimittel Forschung Drug Res 44: 59-64